Pharmaceutical News

RSS

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.

4 May 2015

High Throughput ChIP-seq Assay for Genome-wide Protein-DNA Analysis

Chromatrap®, a business unit of Porvair Sciences, has published a new application note that describes how Chromatrap® ChIP-seq assays now enable unbiased, genome-wide understanding of protein-DNA regulatory networks...

From Chromatrap® - Porvair Sciences Ltd 30 Apr 2015

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses.

30 Apr 2015

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

Eleven IFPMA member companies are involved in the development of new antibiotics. There are currently 34 antibacterial compounds in development (19 molecules and 15 vaccines). Eight compounds are undergoing the final stages of demonstrating their efficacy, quality, and safety (phase 3 clinical trials)...

30 Apr 2015

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

Amerigen Pharmaceuticals Limited today announced that the U.S. Food and Drug Administration has granted tentative approval to the Company's Abbreviated New Drug Application (ANDA) for a generic version of Toviaz (Fesoterodine Fumarate Extended-release Tablets, 4mg and 8mg).

30 Apr 2015

Research provides insights into the ability of FL118 to overcome treatment resistance

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.

30 Apr 2015

Locally procured drugs can be as effective as IQA drugs for treating MDR-TB in Pakistan

Locally-sourced antibiotics can be as effective as 'internationally quality-assured' (IQA) antibiotics for treating multidrug-resistant tuberculosis (MDR-TB) in Pakistan, and may help avoid delays in starting treatment while programmes wait for drugs to arrive from overseas, according to new research published in PLOS ONE.

30 Apr 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer.

29 Apr 2015

SLU selected to work on universal flu vaccine project

Supported by a federal contract, Saint Louis University will study a concept for a universal flu vaccine that is designed to protect people from influenza pandemics that could turn deadly as well as seasonal flu caused by the influenza A virus.

29 Apr 2015

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent are prescribed an oral antiplatelet (OAP) therapy and aspirin to help prevent a heart attack, a blood clot in their heart stent (stent thrombosis), or even death.

28 Apr 2015

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS").

28 Apr 2015

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China granted a process patent for its novel stem-cell based drug Stempeucel.

28 Apr 2015

High-dose flu vaccine more effective than standard dose for elders

If you're age 65 or older and go to your doctor or pharmacy for a flu shot, you may be offered two options: the standard vaccine, or a high-dose version that packs a stronger wallop to activate the immune system, which is weaker in seniors. The Centers for Disease Control and Prevention (CDC) says either vaccine is appropriate for this age group.

28 Apr 2015

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.

27 Apr 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories").

27 Apr 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration.

From Baxter International Inc. 27 Apr 2015

aTyr's Resolaris granted FDA Orphan Drug Designation for treatment of FSHD

aTyr Pharma, a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced today that Resolaris has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

27 Apr 2015

Pharmaceutical News

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

High Throughput ChIP-seq Assay for Genome-wide Protein-DNA Analysis

Texas Biomed scientists awarded NIH grant to develop potential HPV-based HIV vaccine

New research-based pharmaceutical industry report provides insights on how to slow down antimicrobial resistance (AMR) and boost antibiotic R&D

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

Research provides insights into the ability of FL118 to overcome treatment resistance

Locally procured drugs can be as effective as IQA drugs for treating MDR-TB in Pakistan

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

SLU selected to work on universal flu vaccine project

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Survey: 52% of acute coronary syndrome patients don't take their prescribed OAP therapy

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

High-dose flu vaccine more effective than standard dose for elders

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

aTyr's Resolaris granted FDA Orphan Drug Designation for treatment of FSHD

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News